Last deal

$100M

Amount

Post-IPO Equity

Stage

23.10.2023

Date

3

all rounds

$255M

Total amount

date founded

Financing round

General

About Company
Harpoon Therapeutics is a clinical-stage immunotherapy company developing T cell engagers to treat cancer and other diseases.

Industry

Sector :

Subsector :

Keywords :

founded date

01.01.2015

Number of employees

Company Type

For Profit

Last funding type

Post-IPO Equity

IPO status

Private

Description

The company uses its proprietary Tri-specific T cell Activating Construct platform to develop a pipeline of novel T cell engagers, with a focus on solid tumors and hematologic malignancies. Their pipeline products include HPN424, HPN536, and HPN217, with HPN424 currently in Phase 1 clinical trial for prostate cancer treatment. For more information, visit their website at www.harpoontx.com.
Contacts

Contact Email

Phone number

Social url

Similar Companies
1000
Juno Therapeutics

Juno Therapeutics

Juno Therapeutics is developing cell-based cancer immunotherapies.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Financial Services

Location

Seattle, WA, USA

total rounds

3

total raised

$310M

count Of Investments

3
Adaptimmune

Adaptimmune

Adaptimmune develops T cell therapies to treat cancer, human immunodeficiency virus, and infectious diseases.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Therapeutics

Location

York, UK

total rounds

9

total raised

$499.5M
Prelude Therapeutics

Prelude Therapeutics

Prelude Therapeutics develops novel therapies to target key drivers of cancer cell growth, survival, and resistance.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Therapeutics, Health Care

Location

Wilmington, DE, USA

total rounds

4

total raised

$147M
Ziopharm oncology

Ziopharm oncology

ZIOPHARM Oncology is a biotechnology company developing gene therapy, cell therapy, and cancer immunotherapy products.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Therapeutics

Location

New York, NY, USA

total rounds

9

total raised

$293.39M

Financials

Funding Rounds
5
3

Number of Funding Rounds

$255M

Money Raised

Their latest funding was raised on 23.10.2023. Their latest investor Arix Bioscience. Their latest round Post-IPO Equity

Date 
Funding Round 
Investors 
Money Raised 
Lead 
Arix Bioscience

Arix Bioscience

Arix Bioscience is a global healthcare and life science company.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Venture Capital, Financial Services

Location

London, UK

total rounds

1

total raised

$21.44M

count Of Investments

27

count Of Exists

2
New Leaf Venture Partners

New Leaf Venture Partners

New Leaf Venture Partners is a venture capital firm that invests in healthcare technology companies.

Sector

Closed End Investments

Subsector

Closed End Investments

Location

New York, NY, USA

count Of Investments

138

count Of Exists

33
OrbiMed

OrbiMed

OrbiMed is a healthcare-focused investment firm managing approximately $5 billion in assets.

Sector

Closed End Investments

Subsector

Closed End Investments

Keywords

Financial Services, Venture Capital, Health Care

Location

New York, NY, USA

count Of Investments

559

count Of Exists

82
Co-Investors
Investors
19
3

Number of lead investors

19

Number of investors

Investor 
Lead 
Round 
Partners 
Yes
Post-IPO Equity, Series C
Yes
Post-IPO Equity, Series C
Yes
Post-IPO Equity, Series C
Arix Bioscience

Arix Bioscience

Arix Bioscience is a global healthcare and life science company.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Venture Capital, Financial Services

Location

London, UK

total rounds

1

total raised

$21.44M

count Of Investments

27

count Of Exists

2
OrbiMed

OrbiMed

OrbiMed is a healthcare-focused investment firm managing approximately $5 billion in assets.

Sector

Closed End Investments

Subsector

Closed End Investments

Keywords

Financial Services, Venture Capital, Health Care

Location

New York, NY, USA

count Of Investments

559

count Of Exists

82
New Leaf Venture Partners

New Leaf Venture Partners

New Leaf Venture Partners is a venture capital firm that invests in healthcare technology companies.

Sector

Closed End Investments

Subsector

Closed End Investments

Location

New York, NY, USA

count Of Investments

138

count Of Exists

33

People

Founders
2
Patrick Baeuerle
Patrick Baeuerle

Patrick Baeuerle

Patrick A. Baeuerle, Ph.D., joined MPM in 2015. Patrick is responsible for the development of BiTE antibody Blincyto® (blinatumomab; AMG 103) which was approved within three months by the US FDA for therapy of relapsed/refractory acute lymphoblastic leukemia. He also spearheaded the development of the BiTE technology, the industry- leading T-cell engaging antibody platform.

current job

MPM Capital
MPM Capital

Patrick Baeuerle

Luke Evnin
Luke Evnin

Luke Evnin

Luke Evnin is the Co-Founder and Managing Director of MPM Capital.

current job

CoStim Pharmaceuticals
CoStim Pharmaceuticals

Luke Evnin

Employee Profiles
24
Luke Walker

Luke Walker

Chief Medical Officer

Julie Eastland

Julie Eastland

Chief Executive Officer

Kunal Patel

Corporate development

Frank Lanza

Controller

S Jack Lin

Director, new technologies

Shawn Melley

Project team lead

Georgia Erbez

Georgia Erbez

Chief Financial Officer

Natalie Sacks

Natalie Sacks

Chief Medical Officer

Activity

Recent News
9
News Timeline

The graph reveals the ratio (%) of positive news articles in a chosen time range

month